Content
03/04/2025
Cambridge, MA USA
Garuda Therapeutics
completed $50 million Series A Round funding. Investors include
OrbiMed Advisors, Northpond Ventures, Cormorant Asset Management.
About
Garuda Therapeutics seeks to eliminate the need for stem cell donors for blood stem cell transplants. Garuda’s proprietary off-the-shelf hematopoietic stem cell (HSC) therapies enable self-renewing, HLA compatible and transgene-free HSCs, available immediately for patients. An immediately available, off-the-shelf option for patients could provide much needed strategies in a multitude of blood disorders across oncology, autoimmune indications, rare heme disorders and inborn errors of metabolism by effectively resetting bone marrow function.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
